SG10202109717TA - Cd20 binding molecules and uses thereof - Google Patents

Cd20 binding molecules and uses thereof

Info

Publication number
SG10202109717TA
SG10202109717TA SG10202109717TA SG10202109717TA SG 10202109717T A SG10202109717T A SG 10202109717TA SG 10202109717T A SG10202109717T A SG 10202109717TA SG 10202109717T A SG10202109717T A SG 10202109717TA
Authority
SG
Singapore
Prior art keywords
binding molecules
molecules
binding
Prior art date
Application number
Other languages
English (en)
Inventor
Bruce Keyt
Omar Duramad
Beatrice Tien-Yi Wang
Ramesh Baliga
Fen Zhang
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of SG10202109717TA publication Critical patent/SG10202109717TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
SG10202109717T 2015-03-04 2016-03-04 Cd20 binding molecules and uses thereof SG10202109717TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562128284P 2015-03-04 2015-03-04

Publications (1)

Publication Number Publication Date
SG10202109717TA true SG10202109717TA (en) 2021-10-28

Family

ID=56849117

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202109717T SG10202109717TA (en) 2015-03-04 2016-03-04 Cd20 binding molecules and uses thereof
SG11201707144VA SG11201707144VA (en) 2015-03-04 2016-03-04 Cd20 binding molecules and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201707144VA SG11201707144VA (en) 2015-03-04 2016-03-04 Cd20 binding molecules and uses thereof

Country Status (18)

Country Link
US (2) US10787520B2 (enrdf_load_stackoverflow)
EP (2) EP3957738A1 (enrdf_load_stackoverflow)
JP (3) JP6793655B2 (enrdf_load_stackoverflow)
KR (4) KR20230130148A (enrdf_load_stackoverflow)
CN (2) CN115093479A (enrdf_load_stackoverflow)
AU (3) AU2016226060B2 (enrdf_load_stackoverflow)
BR (1) BR112017018941B8 (enrdf_load_stackoverflow)
CA (1) CA2978324A1 (enrdf_load_stackoverflow)
DK (1) DK3265575T3 (enrdf_load_stackoverflow)
ES (1) ES2874558T3 (enrdf_load_stackoverflow)
HU (1) HUE054642T2 (enrdf_load_stackoverflow)
IL (2) IL297997A (enrdf_load_stackoverflow)
NZ (1) NZ762365A (enrdf_load_stackoverflow)
PL (1) PL3265575T3 (enrdf_load_stackoverflow)
PT (1) PT3265575T (enrdf_load_stackoverflow)
SG (2) SG10202109717TA (enrdf_load_stackoverflow)
SI (1) SI3265575T1 (enrdf_load_stackoverflow)
WO (1) WO2016141303A2 (enrdf_load_stackoverflow)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3041862T3 (da) 2013-09-05 2020-07-27 Igm Biosciences Inc Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde
WO2015113005A1 (en) 2014-01-27 2015-07-30 Molecular Templates, Inc. Mhc class i epitope delivering polypeptides
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
SG10201909716RA (en) 2014-04-03 2019-11-28 Igm Biosciences Inc Modified j-chain
EP3950706A1 (en) 2014-06-11 2022-02-09 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
CA2972990A1 (en) 2015-01-20 2016-07-28 Beatrice Tien-Yi WANG Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
EP3253799B1 (en) 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
CN107921285B (zh) 2015-03-25 2022-06-07 Igm生物科学股份有限公司 多价乙型肝炎病毒抗原结合分子及其应用
HK1245675A1 (zh) 2015-04-17 2018-08-31 Igm Biosciences, Inc. 多价人免疫缺陷病毒抗原结合分子及其用途
HUE051246T2 (hu) 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
DK3356401T3 (da) * 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
WO2017059380A1 (en) * 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
PL3455257T3 (pl) 2016-05-09 2022-01-17 Igm Biosciences Inc. Przeciwciała anty-pd-l1
JP7075134B2 (ja) 2016-12-07 2022-05-25 モレキュラー テンプレーツ，インク． 部位特異的コンジュゲーションのための志賀毒素ａサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子
US20200024312A1 (en) 2017-01-25 2020-01-23 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
CN110536900B (zh) 2017-04-07 2024-06-11 Igm生物科学股份有限公司 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区
KR102745232B1 (ko) 2018-03-01 2024-12-26 아이쥐엠 바이오사이언스 인코포레이티드 IgM 혈청 반감기에 영향을 미치는 IgM Fc 및 J-쇄 돌연변이
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
CN112839677A (zh) * 2018-10-23 2021-05-25 Igm生物科学股份有限公司 基于IgM-Fc和IgA-Fc的多价结合分子
BR112022002780A2 (pt) 2019-08-15 2022-05-10 Igm Biosciences Inc Moléculas de ligação multiméricas imunoestimulatórias
AU2020351205A1 (en) * 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
CA3173414A1 (en) 2020-04-22 2021-10-28 Bruce Keyt Pd-1 agonist multimeric binding molecules
WO2022109023A1 (en) * 2020-11-17 2022-05-27 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
CN112521508B (zh) * 2020-12-29 2021-08-03 郴州宾泽医学检验有限公司 一种cd20抗体及其治疗癌症的应用
WO2022178047A1 (en) * 2021-02-17 2022-08-25 Igm Biosciences, Inc. Anti-cd123 binding molecules and uses thereof
NL2030990B1 (en) * 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
WO2024073700A2 (en) * 2022-09-30 2024-04-04 Igm Biosciences, Inc. Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies
WO2024148336A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. T cell costimulatory multimeric binding molecules and uses thereof
WO2025076144A1 (en) * 2023-10-03 2025-04-10 Atara Biotherapeutics, Inc. Bispecific cd19/cd20-targeted chimeric antigen receptors and uses thereof
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
WO1998030592A1 (en) * 1997-01-10 1998-07-16 Epicyte Pharmaceutical, Inc. Novel epithelial tissue targeting agent
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
WO1999054484A1 (en) 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
US7312318B2 (en) 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
CA2403425C (en) * 2000-04-11 2013-08-27 Genentech, Inc. Multivalent antibodies and uses therefor
ATE442386T1 (de) 2000-04-28 2009-09-15 Planet Biotechnology Inc Immunoadhesin zur impfung gegen rhinovirus
AU2001272908A1 (en) 2000-05-10 2001-11-20 David A. Sirbasku Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
JP4498746B2 (ja) 2002-02-14 2010-07-07 イミューノメディクス、インコーポレイテッド 抗ｃｄ２０抗体およびその融合タンパク質ならびに使用法
WO2003086459A1 (en) 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
CN101824090B (zh) 2002-06-14 2013-01-02 免疫医疗公司 人源化单克隆抗体hPAM4
ES2442615T5 (es) * 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
EP1558648B1 (en) * 2002-10-17 2012-01-11 Genmab A/S Human monoclonal antibodies against cd20
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
CA2521490C (en) 2003-05-23 2013-07-30 Crucell Holland B.V. Production of recombinant igm in per.c6 cells
DE602004030451D1 (de) 2003-07-15 2011-01-20 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm-produktion
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
JP4671864B2 (ja) 2003-10-09 2011-04-20 中外製薬株式会社 タンパク質溶液の安定化方法
DK1673398T3 (da) 2003-10-16 2011-04-18 Micromet Ag Multispecifikke, deimmuniserede CD3-bindere
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
AU2005304973A1 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
JP5214252B2 (ja) 2005-03-03 2013-06-19 イミューノメディクス、インコーポレイテッド ヒト化ｌ２４３抗体
US8349332B2 (en) * 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
ZA200710496B (en) * 2005-06-02 2009-04-29 Astrazeneca Ab Antibodies directed to CD20 and used thereof
CN101263158B (zh) * 2005-08-03 2011-12-28 人类多克隆治疗股份有限公司 表达人源化免疫球蛋白的转基因动物中b细胞凋亡的抑制
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006330051B2 (en) * 2005-12-16 2011-08-18 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007073499A2 (en) 2005-12-21 2007-06-28 Medimmune, Inc. Epha2 bite molecules and uses thereof
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
EP2087111A2 (en) 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
US20100298223A1 (en) 2007-05-02 2010-11-25 Dietmar Rudolf Fries Fibrinogen for treatment of bleeding in trauma and platelet disorders
CN201229536Y (zh) 2008-07-03 2009-04-29 鸿富锦精密工业（深圳）有限公司 电脑机箱
WO2011071957A1 (en) 2009-12-07 2011-06-16 Sea Lane Biotechnologies, Llc Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
NZ600820A (en) 2009-12-29 2014-12-24 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
NZ601580A (en) 2010-02-11 2014-11-28 Alexion Pharma Inc Therapeutic methods using anti-cd200 antibodies
EP3345619A1 (en) 2010-10-19 2018-07-11 Mayo Foundation for Medical Education and Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
UY33826A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión con dominios trivariables y sus usos
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013087911A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
CA2863714C (en) 2012-02-08 2022-07-05 Igm Biosciences, Inc. Cdim binding proteins and uses thereof
US10059777B2 (en) * 2012-04-05 2018-08-28 Gottfried Himmler Secretory immunoglobulin complex
NZ701278A (en) 2012-04-17 2016-12-23 Mayo Foundation Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
US20150175678A1 (en) 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
US9540442B2 (en) 2012-08-02 2017-01-10 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10066238B2 (en) 2013-02-11 2018-09-04 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
DK3041862T3 (da) 2013-09-05 2020-07-27 Igm Biosciences Inc Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
ES2747760T3 (es) 2014-01-16 2020-03-11 Mario Umberto Francesco Mondelli Neutralización de anticuerpos monoclonales humanos contra el antígeno de superficie del virus de la hepatitis B
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
SG10201909716RA (en) * 2014-04-03 2019-11-28 Igm Biosciences Inc Modified j-chain
CA2972990A1 (en) 2015-01-20 2016-07-28 Beatrice Tien-Yi WANG Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN107921285B (zh) 2015-03-25 2022-06-07 Igm生物科学股份有限公司 多价乙型肝炎病毒抗原结合分子及其应用
HK1245675A1 (zh) 2015-04-17 2018-08-31 Igm Biosciences, Inc. 多价人免疫缺陷病毒抗原结合分子及其用途
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
WO2017059380A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
PL3455257T3 (pl) 2016-05-09 2022-01-17 Igm Biosciences Inc. Przeciwciała anty-pd-l1
WO2018017761A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
WO2018017763A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
US20190330360A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
WO2018017888A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
CN110536900B (zh) 2017-04-07 2024-06-11 Igm生物科学股份有限公司 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区
JP7358365B2 (ja) 2018-02-26 2023-10-10 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用
KR102745232B1 (ko) 2018-03-01 2024-12-26 아이쥐엠 바이오사이언스 인코포레이티드 IgM 혈청 반감기에 영향을 미치는 IgM Fc 및 J-쇄 돌연변이
CN112839677A (zh) 2018-10-23 2021-05-25 Igm生物科学股份有限公司 基于IgM-Fc和IgA-Fc的多价结合分子

Also Published As

Publication number Publication date
IL254223B1 (en) 2023-01-01
CN115093479A (zh) 2022-09-23
IL254223B2 (en) 2023-05-01
NZ735607A (en) 2024-01-26
KR102357312B1 (ko) 2022-02-03
NZ762365A (en) 2024-11-29
WO2016141303A3 (en) 2016-11-03
ES2874558T3 (es) 2021-11-05
AU2016226060B2 (en) 2020-04-23
EP3265575A4 (en) 2018-08-08
CN107532188A (zh) 2018-01-02
US20190100597A1 (en) 2019-04-04
KR20220018081A (ko) 2022-02-14
AU2023203119A1 (en) 2023-06-15
DK3265575T3 (da) 2021-05-31
KR20230130148A (ko) 2023-09-11
JP2021036885A (ja) 2021-03-11
EP3265575B1 (en) 2021-04-21
CN107532188B (zh) 2022-05-10
KR20170122258A (ko) 2017-11-03
PL3265575T3 (pl) 2021-11-29
BR112017018941B1 (pt) 2022-03-03
SI3265575T1 (sl) 2021-08-31
KR20240135877A (ko) 2024-09-12
US20210032357A1 (en) 2021-02-04
IL297997A (en) 2023-01-01
US10787520B2 (en) 2020-09-29
JP2023099206A (ja) 2023-07-11
BR112017018941A8 (pt) 2018-06-12
EP3957738A1 (en) 2022-02-23
JP6793655B2 (ja) 2020-12-02
HUE054642T2 (hu) 2021-09-28
AU2020202667A1 (en) 2020-05-14
BR112017018941A2 (pt) 2018-04-17
WO2016141303A2 (en) 2016-09-09
JP2018508214A (ja) 2018-03-29
SG11201707144VA (en) 2017-09-28
BR112017018941B8 (pt) 2023-01-10
AU2016226060A1 (en) 2017-10-12
CA2978324A1 (en) 2016-09-09
PT3265575T (pt) 2021-06-16
IL254223A (en) 2017-10-31
EP3265575A2 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
IL254223A (en) CD20 binding compounds and their uses
IL263799A (en) Multimeric ox40 binding molecules and uses thereof
IL251891B (en) Specific binding molecules for cd73 and their uses
GB201612520D0 (en) Binding molecules
ZA201803841B (en) Binding molecules specific for asct2 and uses thereof
SI3355913T1 (sl) Vezalne molekule z modificirano j-verigo
IL273641B (en) Specific binding molecules for il-21 and uses thereof
GB201702091D0 (en) Specific binding molecules
SG10202111844VA (en) Cxcr4 binding molecules
GB201503812D0 (en) Antibody molecules and uses thereof
IL252932A0 (en) Anti-cxcl12 antibody molecules and their uses
HK1241931A1 (zh) Cd20結合分子及其用途
GB201612534D0 (en) Antibodies and related molecules and uses thereof
GB201508729D0 (en) Binding molecules
GB201604378D0 (en) Antibodies and related molecules and uses thereof